Carrie Brownstein

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

S100A10 regulates plasminogen-dependent macrophage invasion

Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings

Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Breast cancer

Annexin A2/P11 interaction: New insights into annexin A2 tetramer structure by chemical crosslinking, high‐resolution mass spectrometry, and computational modeling

Coordinated regulation of myeloid cells by tumours

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Cancer stem cells revisited

Survivors of childhood and adolescent cancer: life-long risks and responsibilities

Endocrine complications in long-term survivors of childhood cancers

Therapeutic targeting of the angiopoietin–TIE pathway

VEGF in Signaling and Disease: Beyond Discovery and Development

Endocrine Late Effects of Cancer Treatment

Tumour heterogeneity and resistance to cancer therapies

NF-κB, inflammation, immunity and cancer: coming of age

The role of MicroRNAs in human cancer

Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer

Osteonecrosis in Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways

Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection

Combination therapy in combating cancer

The Childhood Cancer Survivor Study: A National Cancer Institute–Supported Resource for Outcome and Intervention Research

Subunit order of eukaryotic TRiC/CCT chaperonin by cross-linking, mass spectrometry, and combinatorial homology modeling

Polysialic acid governs T-cell development by regulating progenitor access to the thymus

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial

Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 Trial

Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study

Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages

Annexin II

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer